Loading
A phase 1/2 trial of Mosunetuzumab, Polatuzumab vedotin, Tocilizumab in hodgkin lymphoma and non-hodgkin lymphoma, run by Hoffmann-La Roche, active and no longer recruiting.
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT03671018 by Hoffmann-La Roche, with 422 participants planned, started 2018-09-25 and due to reach its primary completion in 2024-01-30. Interventions recorded: Mosunetuzumab (IV), Mosunetuzumab (SC), Polatuzumab vedotin, Tocilizumab, Rituximab. Conditions listed: B-cell Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tocilizumab, Mosunetuzumab, Roche / Genentech, T-cell engagers (bispecific).
Shares Tocilizumab, Mosunetuzumab, Roche / Genentech, T-cell engagers (bispecific).
Shares Polatuzumab vedotin, Tocilizumab, T-cell engagers (bispecific), Hodgkin lymphoma.
Shares Mosunetuzumab, Rituximab, Roche / Genentech, T-cell engagers (bispecific).
Shares Polatuzumab vedotin, Mosunetuzumab, Roche / Genentech, T-cell engagers (bispecific).
Shares Rituximab, Roche / Genentech, T-cell engagers (bispecific), Hodgkin lymphoma.
Shares Tocilizumab, Roche / Genentech, T-cell engagers (bispecific), Non-Hodgkin lymphoma (all types).
Shares Tocilizumab, Roche / Genentech, T-cell engagers (bispecific), Non-Hodgkin lymphoma (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/